Grace TherapeuticsGRCE +0.65%31 PB Ratio is 0.59 as of Jun. 25, 2026, which is 37% above its 10-year median of 0.43. GuruFocus rates GRCE with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,233 Biotechnology companies, Grace Therapeutics ranks better than 92.86% on this metric.
Grace Therapeutics Inc stock PB Ratio (=0.58) is close to 3-year high of 0.58.
The historical rank and industry rank for Grace Therapeutics's PB Ratio or its related term are showing as below:
GRCE'
s PB Ratio Range Over the Past 10 Years
Min: 0.12 Med: 0.43 Max: 6.25
Current: 0.59
During the past 13 years, Grace Therapeutics's highest PB Ratio was 6.25. The lowest was 0.12. And the median was 0.43.
GRCE's PB Ratio is ranked better than 92.86% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs GRCE: 0.59
During the past 12 months, Grace Therapeutics's average Book Value Per Share Growth Rate was -17.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -24.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -23.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -23.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Grace Therapeutics was 166.30% per year. The lowest was -61.60% per year. And the median was 2.40% per year.
Back to Basics: PB Ratio
Grace Therapeutics (NAS:GRCE) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Grace Therapeutics PB Ratio Related Terms
Grace Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Grace Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Grace Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grace Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Grace Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Grace Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Grace Therapeutics (GRCE) has a PB Ratio of 0.59 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Grace Therapeutics and its competitors. This is 37% above median its historical median of 0.43. Over the past decade, Grace Therapeutics' PB Ratio has ranged from 0.12 to 6.25. According to the industry distribution chart, Grace Therapeutics ranks #88 out of 1233 companies in the Biotechnology industry, placing it in the top 7.1%.
Is Grace Therapeutics' PB Ratio too high?
Grace Therapeutics' current PB Ratio of 0.59 is 37% above median its 10-year median of 0.43. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 6.25. The Biotechnology industry median PB Ratio is 2.80. Grace Therapeutics' value of 0.59 is 78.9% below this industry median. Based on the distribution chart, Grace Therapeutics ranks #88 out of 1233 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Grace Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Grace Therapeutics' PB Ratio compare to PSTV and ATNM?
According to the Biotechnology industry distribution chart, Grace Therapeutics ranks #88 out of 1233 companies for PB Ratio. This places Grace Therapeutics in the top 7% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. Grace Therapeutics' value of 0.59 is 78.9% below this benchmark. Historically, Grace Therapeutics' own PB Ratio has ranged from 0.12 to 6.25 over the past decade. While the company's 10-year median is 0.43 vs. the industry median of 2.80, Grace Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grace Therapeutics's current PB Ratio of 0.59 is 78.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Grace Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grace Therapeutics's current PB Ratio is 0.59, which is 37% above median its own 10-year median of 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grace Therapeutics stock overvalued right now?
Grace Therapeutics (GRCE) has a current PB Ratio of 0.59. The current PB Ratio is 0.59, which is 37% above median its 10-year median of 0.43 and 78.9% below the Biotechnology industry median of 2.80. Grace Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Grace Therapeutics (GRCE), the current PB Ratio is 0.59 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
31GF Score
Get the complete analysis for GRCE
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRCE has been successfully added to your 
